I
am writing in regards to an inaccuracy in the recent case report published in the Journal of Community Hospital Internal Medicine Perspectives by Karmacharya et al. (1) . The authors had stated that sodium zirconium cyclosilicate (ZS-9) along with patiromer sorbitex calcium (patiromer) has not been studied in patients with serum potassium (K ' ) concentrations !6.5 mEq/L. However, it should be noted that while it is true that the phase III trial of patiromer did not include patients with serum K ' !6.5 mEq/L, that is not the case with ZS-9. Specifically, we would like to point out that:
1. There was no upper limit of baseline serum K ' specified for patient inclusion in the ZS-9 HARMONIZE study (2). 2. The HARMONIZE study included nine patients with baseline serum K ' !6.5 mEq/L (up to 7.2 mEq/L). 3. The mean baseline serum K ' of HARMONIZE study patients was 5.6 mEq/L (2). 4. A Letter to the Editor published in the New England Journal of Medicine described analyses conducted on a combined cohort of 45 patients with baseline serum K ' from 6.1 to 7.2 mEq/L from two Phase III ZS-9 studies (ZS003 and HARMONIZE) (3). The mean baseline serum K ' concentration of this combined cohort was 6.3 mEq/L.
With these data in mind, I affirm to the reader that there are published clinical data of ZS-9 treatment achieving normokalemia in patients with baseline serum K ' !6.5 mEq/L.
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